Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is not a lawyer or financial adviser. All information is derived from publicly available sources and may not be complete or current. Details regarding transactions, royalty structures, and financial arrangements may

Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is not a lawyer or financial adviser. All information is derived from publicly available sources and may not be complete or current. Details regarding transactions, royalty structures, and financial arrangements may

Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is not a lawyer or financial adviser. All information is derived from publicly available sources and may not be complete or current. Details regarding transactions, royalty structures, and financial arrangements may

Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is not a lawyer or financial adviser. All information is derived from publicly available sources and may not be complete or current. Details regarding transactions, royalty structures, and financial arrangements may

China's biotech venture capital (VC) sector in 2025 is recovering from a deep slump. After peaking at $15.7 billion invested in 2021, annual venture funding for Chinese biotechs plummeted to just $4.2 billion in 2024, amid a broader market downturn. This decline was driven in large

Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is not a lawyer or financial adviser. All information is derived from publicly available sources and may not be complete or current. Details regarding transactions, royalty structures, and financial arrangements may

DISCLAIMER This article is provided for informational and educational purposes only. It does not constitute legal, financial, tax, or investment advice. All information presented is derived from publicly available sources including corporate press releases, regulatory filings, Swiss Official Gazette entries, and published tax law provisions. The author is not a

Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is not a lawyer or financial adviser. All information is derived from publicly available sources and may not be complete or current. Details regarding transactions, royalty structures, and financial arrangements may

Company Overview and Corporate Structure Elevara Medicines Ltd. is a London-based clinical-stage biotechnology company focused on innovative therapies for rheumatoid arthritis (RA) and related inflammatory diseases. The company was co-founded in 2025 by Weatherden, a UK clinical development advisory firm, together with venture investor Monograph Capital. Weatherden&

Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is not a lawyer or financial adviser. All information is derived from publicly available sources and may not be complete or current. Details regarding transactions, royalty structures, and financial arrangements may